It is worth noting that immune checkpoint blockade has been shown to yield responses even in patients with PD-L1-negative tumours, highlighting the complex role of PD-L1 as a predictive biomarker for immune checkpoint blockade [51,[91], [92], [93]]. Here, CD274 is linked to neoplasm.